OBJECTIVE: Spontaneous arthritis in the KRN transgenic mouse model is due to the autoreactivity of the transgenic T cell receptor (TCR) against Ag7 major histocompatibility complex (MHC) molecules, which leads to strong but incomplete clonal deletion. We sought to determine whether other stimuli triggering this receptor might provoke arthritis, whether the apparently systemic reactivity might have some joint-preferential component explaining the paradoxical arthritic phenotype, and whether the transgenic receptor was the only one required or whether other TCRs might be ferried along in a leaky tolerance process. METHODS: Crosses and radiation chimeras involving a panel of transgenic and knockout mouse lines were used. The reactivity of the KRN TCR was tested in carboxyfluorescein diacetate succinimidyl ester-transfer experiments and in crosses with transgenic or inbred mice expressing other molecules that stimulate the KRN receptor (the mls-1a superantigen, the Aalpha(k69)Abeta(k) mutant MHC molecule). The arthritogenic capacity of T cells expressing only the KRN TCR was tested by crossing to recombination-activating gene-knockout mice, and constructing bone marrow chimeras with precursors to these strictly monoclonal T cells. RESULTS: The data show that the KRN TCR itself is the only receptor needed. It needs to be triggered by the Ag7 molecule loaded with self-peptides in order to provoke arthritis, but there is no indication of preferential presentation of joint-derived peptides. CONCLUSION: Arthritis can be generated by systemic recognition of self-MHC-peptide complexes by autoreactive T cells. This triggers B lymphocytes to produce arthritogenic antibodies, without the involvement of joint-specific T cell targets.
OBJECTIVE: Spontaneous arthritis in the KRN transgenic mouse model is due to the autoreactivity of the transgenic T cell receptor (TCR) against Ag7 major histocompatibility complex (MHC) molecules, which leads to strong but incomplete clonal deletion. We sought to determine whether other stimuli triggering this receptor might provoke arthritis, whether the apparently systemic reactivity might have some joint-preferential component explaining the paradoxical arthritic phenotype, and whether the transgenic receptor was the only one required or whether other TCRs might be ferried along in a leaky tolerance process. METHODS: Crosses and radiation chimeras involving a panel of transgenic and knockout mouse lines were used. The reactivity of the KRN TCR was tested in carboxyfluorescein diacetate succinimidyl ester-transfer experiments and in crosses with transgenic or inbred mice expressing other molecules that stimulate the KRN receptor (the mls-1a superantigen, the Aalpha(k69)Abeta(k) mutant MHC molecule). The arthritogenic capacity of T cells expressing only the KRN TCR was tested by crossing to recombination-activating gene-knockout mice, and constructing bone marrow chimeras with precursors to these strictly monoclonal T cells. RESULTS: The data show that the KRN TCR itself is the only receptor needed. It needs to be triggered by the Ag7 molecule loaded with self-peptides in order to provoke arthritis, but there is no indication of preferential presentation of joint-derived peptides. CONCLUSION:Arthritis can be generated by systemic recognition of self-MHC-peptide complexes by autoreactive T cells. This triggers B lymphocytes to produce arthritogenic antibodies, without the involvement of joint-specific T cell targets.
Authors: Toshio Yoshizawa; Deepa Hammaker; David L Boyle; Maripat Corr; Richard Flavell; Roger Davis; Georg Schett; Gary S Firestein Journal: J Immunol Date: 2009-06-26 Impact factor: 5.422
Authors: Narendiran Rajasekaran; Nan Wang; Phi Truong; Cornelia Rinderknecht; Claudia Macaubas; Georg F Beilhack; Judith A Shizuru; Elizabeth D Mellins Journal: Arthritis Rheum Date: 2013-03
Authors: Ferenc Boldizsar; Katalin Kis-Toth; Oktavia Tarjanyi; Katalin Olasz; Akos Hegyi; Katalin Mikecz; Tibor T Glant Journal: Arthritis Rheum Date: 2010-10
Authors: Yukiko Maeda; Nicholas H Farina; Melissa M Matzelle; Paul J Fanning; Jane B Lian; Ellen M Gravallese Journal: J Bone Miner Res Date: 2016-10-28 Impact factor: 6.741
Authors: Tomoko Hayashi; Brian Crain; Shiyin Yao; Christa D Caneda; Howard B Cottam; Michael Chan; Maripat Corr; Dennis A Carson Journal: J Pharmacol Exp Ther Date: 2014-06-03 Impact factor: 4.030